Estonia Pharmaceuticals and Healthcare Report Q4 2013

Business Monitor International Market Research Reports Market Reports Online XML Feed

2012 Intl Green Construction Code Sign up for the most comprehensive introductory course available on the web for the 2012 International Green Construction Code (IgCC). Just $29. From our sponsors

Estonia Pharmaceuticals and Healthcare Report Q4 2013 Aug 28th 2013, 00:00 Price: $ 1295   BMI View: Strong Q113 results underpin our expectations for further growth in Estonia's pharmaceutical sales in 2013. An improving macroeconomic picture, real wage growth and higher employment figures point to a rise in state tax revenues. We therefore expect funding for healthcare to rise, particularly in light of the country's ageing population. Nevertheless, on an absolute basis, the Estonian pharmaceutical market remains relatively small in comparison to regional markets in Central and Eastern Europe. Despite its transparent regulatory policies, business-friendly operating environment and strong pharmaceutical sales in 2012, the country continues to present drugmakers with limited opportunities. Headline Expenditure Projections ? Pharmaceuticals: EUR262mn (US$330mn) in 2012 to EUR276mn ( ... Complete report details with Table of Contents and more @ http://www.marketreportsonline.com/268630.html

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions